Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors
“We are extremely pleased that
Dr. Greig also serves on the boards of Genocea Biosciences and the Edinburgh BioQuarter Commercialisation Advisory Group, and is a member of the Imperial College Innovations Healthcare Advisory Board and a board observer for Anaphore, Inc. He holds a Ph.D. in Biochemistry from the University of
About Rib-X Pharmaceuticals, Inc.
Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. NDAs for Rib-X’s most advanced compounds, delafloxacin and radezolid, are anticipated in the 2011/2012 timeframe. The Company’s underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company’s integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X’s iterative intelligent engine has yielded several distinctive new antibiotics that can be used for the treatment of either community- or hospital-acquired infections. The Company has recently completed Phase 2 trials in complicated skin and skin structure infections with the IV form of delafloxacin (RX-3341), and is currently in Phase 2 trials with radezolid (RX-1741), an oxazolidinone that was discovered at Rib-X, as an oral/IV agent for treatment of serious Gram-positive infections and community or hospital acquired pneumonias. The Rx-04 discovery program is developing novel classes of antibiotics active against multi-drug resistant Gram-negative bacteria and the Rx-02 discovery program is focused on developing an IV/oral macrolide active against methicillin-resistant S. aureus, multidrug-resistant Streptococcus pneumoniae and S. pyogenes.
For more information on the Rib-X mission and the pipeline, please visit the Company website at www.rib-x.com.
For further information please contact:
Media: Irma Gomez-Dib FD Life Sciences Tel: 212-850-5761 firstname.lastname@example.org Investors: John Capodanno FD Life Sciences Tel: 212-850-5705 John.email@example.com
SOURCE Rib-X Pharmaceuticals, Inc.